Meeting
2024 ASCO Gastrointestinal Cancers Symposium
Association between TP53 gain of function and loss of function mutational subgroups and survival in pancreatic adenocarcinoma.
Authors
Nitzan Zohar
Thomas Jefferson University, Philadelphia, PA
Nitzan Zohar , Edik Matthew Blais , Adam Mueller , Dzung Thach , Patricia Miren de Arbeloa , Lynn McCormick Matrisian , Emanuel Petricoin III, Michael J. Pishvaian , Andrew Eugene Hendifar , Atrayee Basu Mallick , Harish Lavu , Charles J. Yeo , Babar Bashir , Avinoam Nevler
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Track
Pancreatic Cancer,Hepatobiliary Cancer,Neuroendocrine/Carcinoid,Small Bowel Cancer
Sub Track
Tumor Biology, Biomarkers, and Pathology
Citation
J Clin Oncol 42, 2024 (suppl 3; abstr 694)
DOI
10.1200/JCO.2024.42.3_suppl.694
Abstract #
694
Poster Bd #
N3
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Gastrointestinal Cancers Symposium
The impact of Wnt pathway alterations including RNF43, GNAS, CTNNB1, and APC on prognosis and potential therapeutic vulnerability in pancreatic adenocarcinoma (PDAC).
First Author: Naoko Takebe
Poster
2022 ASCO Annual Meeting
Evaluation of stage IV pancreatic adenocarcinomas based on mutational profiling of tumors.
First Author: Katherine E Poruk
Poster
2023 ASCO Annual Meeting
Not all treated KRAS-mutant pancreatic adenocarcinomas are equal: KRAS G12D and survival outcome.
First Author: Bach Ardalan
Poster
2022 ASCO Annual Meeting
Analysis of molecular characterization: Pancreatic ductal adenocarcinoma with hepatic metastases.
First Author: Yonggang He